Neutrophil-to-lymphocyte ratio as an independent predictor for survival in patients with localized clear cell renal cell carcinoma after radiofrequency ablation: a propensity score matching analysis

Chang, Xiaofeng; Zhang, Fan; Liu, Tieshi; Wang, Wei; Guo, Hongqian

doi:10.1007/s11255-017-1554-6

Cited by 17 publications

(20 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A summary of 18 recent studies investigating the prognostic role of NLR in RCC is shown in Table . A total of 10 studies included mainly metastatic patients; in eight studies, the main treatment was molecular‐targeted agents; and in two studies, the treatment was cytoreductive nephrectomy.…”

Section: Differential Blood Cell Markersmentioning

confidence: 99%

“…Furthermore, post‐treatment NLR was a significant prognostic factor of CSS. Another study of post‐treatment changes in NLR was carried out by Chang et al . They analyzed the association among preoperative NLR, postoperative change in NLR and survival in patients who underwent radiofrequency ablation for localized RCC.…”

Section: Differential Blood Cell Markersmentioning

confidence: 99%

“…96 Furthermore, post-treatment NLR was a significant prognostic factor of CSS. Another study of post-treatment changes in NLR was carried out by Chang et al 104 They analyzed the association among preoperative NLR, postoperative change in NLR and survival in patients who underwent radiofrequency ablation for localized RCC. They showed that elevated preoperative NLR ≥2.79 and a change of NLR ≥0.4 were significantly associated with poor DFS; in particular, patients with both factors had the worst DFS.…”

Section: Nlr In Rccmentioning

confidence: 99%

See 2 more Smart Citations

Role of systemic inflammatory response markers in urological malignancy

Ohno

2018

Int J of Urology

View full text Add to dashboard Cite

The systemic inflammatory response is associated with survival in patients with a variety of cancers. This inflammatory response is measured in the peripheral blood, and can be monitored using two categories of indices: concentration of specific serum proteins (albumin, C‐reactive protein) and differential blood cell count (neutrophils, lymphocytes and platelets). Furthermore, combinations of these indices, such as the Glasgow Prognostic Score, which consists of the serum C‐reactive protein and albumin level; the neutrophil‐to‐lymphocyte ratio; the platelet‐to‐lymphocyte ratio; and the prognostic nutritional index, which is based on peripheral blood lymphocyte count and serum albumin level, have also been evaluated and compared in cancer research. To date, there are hundreds of studies that have shown the prognostic value of systemic inflammatory response markers in patients with urological cancer. Most studies have evaluated the prognostic and predictive role of the pretreatment value of the markers, although some have focused on the role of the post‐treatment value at specific points during the clinical course. The advantages of systemic inflammatory response markers are that they are easily measurable and inexpensive in the clinical setting. However, it is important to consider how clinicians use these markers in clinical practice. The present review provides a concise overview regarding systemic inflammatory markers in urological cancers, specifically C‐reactive protein, Glasgow Prognostic Score/modified Glasgow Prognostic Score, neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio and prognostic nutritional index.

show abstract

Section: Differential Blood Cell Markersmentioning

confidence: 99%

Section: Differential Blood Cell Markersmentioning

confidence: 99%

Section: Nlr In Rccmentioning

confidence: 99%

See 1 more Smart Citation

Role of systemic inflammatory response markers in urological malignancy

Ohno

2018

Int J of Urology

View full text Add to dashboard Cite

show abstract

“…Elevated neutrophil-to-lymphocyte ratio (.5) is an independent predictor of worse survival in patients who undergo 90 Y TARE for colorectal metastases in liver (102). High preoperative neutrophil-to-lymphocyte ratio (.2.79) and elevated postoperative neutrophil-to-lymphocyte ratio was associated with a significant increase in risk of local recurrence and distant metastasis after RFA of renal cell cancer (103). However, lymphocyte-to-monocyte ratio is predictive of survival after RFA for colorectal liver metastases (104).…”

Section: Combining Io Therapies With Immunotherapymentioning

confidence: 99%

Immunotherapy and the Interventional Oncologist: Challenges and Opportunities—A Society of Interventional Oncology White Paper

Erinjeri¹,

Fine²,

Adema³

et al. 2019

Radiology

View full text Add to dashboard Cite

Interventional oncology is a subspecialty field of interventional radiology that addresses the diagnosis and treatment of cancer and cancer-related problems by using targeted minimally invasive procedures performed with image guidance. Immuno-oncology is an innovative area of cancer research and practice that seeks to help the patient's own immune system fight cancer. Both interventional oncology and immuno-oncology can potentially play a pivotal role in cancer management plans when used alongside medical, surgical, and radiation oncology in the care of cancer patients.

show abstract

“…28 Decreased post-RFA neutrophil-lymphocyte ratio (NLR) was associated with improved disease-free survival in 178 small hepatocellular carcinoma (HCC) patients, 29 while increased postablation NLR was associated with local recurrence and metastatic disease in patients with 185 renal cell carcinoma (RCC) patients treated with RFA. 30 Additionally, an increase in the number of interferon gamma (IFN-γ) producing cytotoxic natural killer (NK) cells was associated with longer disease-free survival after RFA in 37 subjects with HCC. 31…”

Section: Cellular Injury and Immunogenicity Of Thermal Ablative Therapymentioning

confidence: 99%

Postablation Immune Microenvironment: Synergy between Interventional Oncology and Immuno-oncology

Kim

Erinjeri

2019

Semin intervent Radiol

View full text Add to dashboard Cite

Current tumor thermal ablation techniques rely on extreme temperatures to induce irreversible cellular injury and coagulative tissue necrosis. Ablation-induced cellular injury or death releases cancer neoantigens and activates the cancer-immunity cycle, potentially generating tumor-specific immune effectors. However, multiple negative regulatory modulators exist at each step of the cycle, mitigating meaningful and therapeutic anticancer effect provided by the immune system. Recent studies have focused on the introduction and testing of adjuvant immunotherapy combined with ablation to synergistically shift the equilibrium out of inhibitory immune modulation. This article reviews the immune microenvironment in relation to image-guided ablation techniques and discusses current and upcoming novel strategies to take advantage of antitumor immunity.

show abstract

Neutrophil-to-lymphocyte ratio as an independent predictor for survival in patients with localized clear cell renal cell carcinoma after radiofrequency ablation: a propensity score matching analysis

Cited by 17 publications

References 27 publications

Role of systemic inflammatory response markers in urological malignancy

Role of systemic inflammatory response markers in urological malignancy

Immunotherapy and the Interventional Oncologist: Challenges and Opportunities—A Society of Interventional Oncology White Paper

Postablation Immune Microenvironment: Synergy between Interventional Oncology and Immuno-oncology

Contact Info

Product

Resources

About